Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1371-1376

  Morris, Heather K ^a   Canetta, Pietro A ^a   Appel, Gerald B ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

ALMS; lupus nephritis; MAINTAIN; maintenance

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CYTOPENIA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ALMS; LUPUS NEPHRITIS; MAINTAIN; MAINTENANCE;

CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; LUPUS NEPHRITIS; REMISSION INDUCTION;

EID: 84879865570     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs447     Document Type: Review

References (25)

1. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
2. Swaak AJ, van den Brink HG, Smeenk RJ et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10: 51-58
3. Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264
4. Mosca M, Bencivelli W, Neri R et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61: 1502-1509
5. Moroni G, Gallelli B, Quaglini S et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-1548
6. Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006; 21: 1465-1469
7. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002
8. Moroni G, Quaglini S, Maccario M et al. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053
9. Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005; 14: 49-52
10. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010; 69: 2083-2089
11. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
12. Gourley MF, Austin HA, 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557
13. Flanc RS, Roberts MA, Strippoli GF et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; CD002922
14. Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355 e25-33
15. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38: 1120-1127
16. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
17. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112
18. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131
19. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year followup data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
20. Stoenoiu MS, Aydin S, Tektonidou M et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012; 27: 1924-1930
21. Korbet SM, Schwartz MM, Evans J et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18: 244-254
22. Barr RG, Seliger S, Appel GB et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18: 2039-2046
23. Als-Nielsen B, Chen W, Gluud C et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928
24. Shekelle P. Pharmaceutical company-sponsored drug trials: what are we to believe? J Clin Epidemiol 2010; 63: 126-127
25. Angell M. Industry-sponsored clinical research: a broken system. JAMA 2008; 300: 1069-1071